# To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Study · id `cardio:ct-nct05699408` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05699408](<https://clinicaltrials.gov/study/NCT05699408>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05699408

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 513 participants.

## Technical summary

Registry record NCT05699408. Randomized; no masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-11-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 513 participants (enrolled count; ClinicalTrials.gov record NCT05699408, source copy `cardio:ctgov-nct05699408-2025-02-18`, retrieved 2026-10-26)
- Started: 2023-03-31 (actual) (ClinicalTrials.gov record NCT05699408, source copy `cardio:ctgov-nct05699408-2025-02-18`, retrieved 2026-10-26)
- Primary completion: 2024-11-23 (actual) (ClinicalTrials.gov record NCT05699408, source copy `cardio:ctgov-nct05699408-2025-02-18`, retrieved 2026-10-26)
- Completion: 2024-11-23 (actual) (ClinicalTrials.gov record NCT05699408, source copy `cardio:ctgov-nct05699408-2025-02-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05699408, source copy `cardio:ctgov-nct05699408-2025-02-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05699408-2025-02-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
- Condition: Type 2 Diabetes
- Intervention (Drug): INS068 injection
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: da3e081e348b468b76ee7ef5e84a3ad85913e12003b243f88446a40e72511e88
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
